Trial Profile
The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Sitagliptin
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DIVERSITY-CVR study
- 06 Oct 2023 Results of sub-analysis of the DIVERSITY-CVR study assessing Effects of sitagliptin versus dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 11 Jun 2019 Primary endpoint (Ratio of achieving a composite endpoint of the following 3 items from baseline to the 24th week 1. HbA1c below 7% 2. Body weight loss of 3% 3. Avoidance of hypoglycemia (Level 2)) has been met as per results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association